Log in
NASDAQ:SRDX

Surmodics Competitors

$38.12
+0.91 (+2.45 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$36.98
Now: $38.12
$38.32
50-Day Range
$35.18
MA: $39.13
$43.09
52-Week Range
$22.06
Now: $38.12
$49.00
Volume41,859 shs
Average Volume66,916 shs
Market Capitalization$518.66 million
P/E Ratio68.07
Dividend YieldN/A
Beta0.98

Competitors

Surmodics (NASDAQ:SRDX) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying SRDX stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Surmodics, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Abbott Laboratories and Surmodics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
Surmodics00303.00

Abbott Laboratories presently has a consensus price target of $115.3750, suggesting a potential upside of 5.59%. Surmodics has a consensus price target of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher probable upside, analysts plainly believe Surmodics is more favorable than Abbott Laboratories.

Risk and Volatility

Abbott Laboratories has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by company insiders. Comparatively, 7.7% of Surmodics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Abbott Laboratories and Surmodics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73
Surmodics$100.08 million5.18$7.59 million$0.7252.94

Abbott Laboratories has higher revenue and earnings than Surmodics. Abbott Laboratories is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Surmodics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Surmodics7.39%7.49%5.90%

Summary

Abbott Laboratories beats Surmodics on 8 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Medtronic and Surmodics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132012.84
Surmodics00303.00

Medtronic presently has a consensus price target of $118.1538, suggesting a potential upside of 6.47%. Surmodics has a consensus price target of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher probable upside, analysts plainly believe Surmodics is more favorable than Medtronic.

Risk and Volatility

Medtronic has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 7.7% of Surmodics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Medtronic and Surmodics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18
Surmodics$100.08 million5.18$7.59 million$0.7252.94

Medtronic has higher revenue and earnings than Surmodics. Medtronic is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and Surmodics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
Surmodics7.39%7.49%5.90%

Summary

Surmodics beats Medtronic on 8 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Stryker and Surmodics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
Surmodics00303.00

Stryker presently has a consensus price target of $221.44, suggesting a potential downside of 4.97%. Surmodics has a consensus price target of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher probable upside, analysts plainly believe Surmodics is more favorable than Stryker.

Risk and Volatility

Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 7.7% of Surmodics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Stryker and Surmodics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.88$2.08 billion$8.2628.21
Surmodics$100.08 million5.18$7.59 million$0.7252.94

Stryker has higher revenue and earnings than Surmodics. Stryker is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and Surmodics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Surmodics7.39%7.49%5.90%

Summary

Stryker beats Surmodics on 9 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Earnings and Valuation

This table compares Intuitive Surgical and Surmodics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27
Surmodics$100.08 million5.18$7.59 million$0.7252.94

Intuitive Surgical has higher revenue and earnings than Surmodics. Surmodics is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Intuitive Surgical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares Intuitive Surgical and Surmodics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Surmodics7.39%7.49%5.90%

Insider and Institutional Ownership

86.9% of Intuitive Surgical shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 7.7% of Surmodics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Intuitive Surgical and Surmodics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical371202.41
Surmodics00303.00

Intuitive Surgical presently has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Surmodics has a consensus price target of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher probable upside, analysts plainly believe Surmodics is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats Surmodics on 9 of the 14 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Valuation & Earnings

This table compares Becton, Dickinson and and Surmodics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40
Surmodics$100.08 million5.18$7.59 million$0.7252.94

Becton, Dickinson and has higher revenue and earnings than Surmodics. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Becton, Dickinson and and Surmodics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
Surmodics7.39%7.49%5.90%

Insider and Institutional Ownership

74.4% of Becton, Dickinson and shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 0.1% of Becton, Dickinson and shares are held by insiders. Comparatively, 7.7% of Surmodics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Becton, Dickinson and and Surmodics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07712.60
Surmodics00303.00

Becton, Dickinson and currently has a consensus target price of $280.2857, suggesting a potential upside of 22.67%. Surmodics has a consensus target price of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher possible upside, analysts plainly believe Surmodics is more favorable than Becton, Dickinson and.

Summary

Surmodics beats Becton, Dickinson and on 8 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Surmodics (NASDAQ:SRDX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Valuation & Earnings

This table compares Edwards Lifesciences and Surmodics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54
Surmodics$100.08 million5.18$7.59 million$0.7252.94

Edwards Lifesciences has higher revenue and earnings than Surmodics. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Surmodics has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Edwards Lifesciences and Surmodics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
Surmodics7.39%7.49%5.90%

Insider and Institutional Ownership

79.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 89.8% of Surmodics shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by insiders. Comparatively, 7.7% of Surmodics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Edwards Lifesciences and Surmodics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences251302.55
Surmodics00303.00

Edwards Lifesciences currently has a consensus target price of $87.7222, suggesting a potential upside of 3.57%. Surmodics has a consensus target price of $66.6667, suggesting a potential upside of 74.89%. Given Surmodics' stronger consensus rating and higher possible upside, analysts plainly believe Surmodics is more favorable than Edwards Lifesciences.

Summary

Edwards Lifesciences beats Surmodics on 8 of the 14 factors compared between the two stocks.


Surmodics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27+1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97+0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01+0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05+1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48+1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70+0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33+1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79+1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77+1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09+1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57+0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89+0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07+1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14+0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09+3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50+0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50+1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55+0.1%$6.52 billion$2.91 billion31.47
Globus Medical logo
GMED
Globus Medical
1.5$58.47+1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78+0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32+2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37+2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24+1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90+1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87+4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14+2.7%$718.07 million$459.95 million30.95
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98+1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94+1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.